Ocular Therapeutix Inc. diskutieren
Ocular Therapeutix Inc.
WKN: A1180P / Symbol: OCUL / Name: Ocular / Aktie / Ausrüstung & Versorgung / Small Cap /
$ Ocul eingeleitet mit einem Übergewicht bei Cantor. $ 35 PT
hat
Ocur looks significantly undervalued,
given the likelihood of approval and potential of Dextenza. The company also has several other compounds in development. The company ended 2016 with just under $70 million in cash on hand and has a quarterly burn rate of less than $10 million. The shares currently sell for approximately one third the median analyst price target and I would not be surprised if the shares run up into that all-important July PDUFA date.
klostergang stimmt der Buy-Einschätzung von tamam zu
klostergang stimmt am 24.06.2017 der Buy-Einschätzung von tamam mit dem Kursziel 20$ zu.Überschrift: Ocur looks significantly undervalued,
SecteurEquipement, fournitures et distribution médicale Agenda 14/11 Publication de résultats
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Nombre d'employés : 119 personnes.
Secteur Equipement, fournitures et distribution médicale Agenda 08/05 Publication de résultats
Nombre d'employés
: 119 personnes.
stratec stimmt dem Sentiment von 'Buy' zu
Over the weekend, JMP Securities reteirated their Buy rating and $9 price target on Ocular Therapeutix JMP's analyst noted 'the FDA approved Dextenza's sNDA for treating ocular inflammation following
ophthalmic surgery, roughly five months earlier than expected. He believes Dextenza will launch with both pain and inflammation indications and forecasts about $12 million of Dextenza sales in 2019, with a majority coming in the fourth quarter. Ocular has been "firing on all cylinders" since Dextenza was approved for both pain and inflammation and securing a C-code and a T-code'
Neueste Beiträge
Lokrim in Capricor Therapeutics Inc diskutieren